ProPhase Labs, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period
ProPhase Labs, Inc. (PRPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period of 51.00 thousand shares for the 12-month period ending 2015-12-31, per its 10-K/A filed 2018-08-20.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod · last filed 2018-08-20
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, equity instruments other than options, grants in period for fiscal 2015 was 51.00K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period 12 month |
|---|---|
| 2015-12-31 | 51.00K shares 10-K/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |